An experimental pill could slow memory loss and brain shrinkage in some Alzheimer’s patients, new research suggests. The pill, called ALZ-801 (valiltramiprosate), was shown to be effective in people ...

Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that ...

Add Yahoo as a preferred source to see more of our stories on Google. Novo Nordisk won't add Alzheimer's disease to the list of conditions its blockbuster diabetes and weight-loss drugs, Ozempic and ...

“Pothead” could one day get a whole new meaning. A new study suggests low doses of THC, the main psychoactive ingredient in ...

In April, the future was looking bleak for an experimental Alzheimer's drug called valiltramiprosate, or ALZ-801. Researchers had just released topline results of a study of more than 300 people age ...

Campaigners have blasted the move as a "major disappointment”.

A mathematical model simulated patient outcomes when given caregiver support or an expensive Alzheimer’s drug to determine cost and health benefits.

Experts see shift toward tailored cancer therapy model Lilly awaiting details of Novo's failed trial Some drug developers target multiple biomarkers Sign up here. Globally, over 55 million people have ...

Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings, with adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer's drug maker reported revenues of ...